ClinicalTrials.gg
Not yet recruitingNCT07852195Updated Oct 1, 2026

Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

A Phase 2/3 interventional study of Abiraterone Acetate and Biospecimen Collection in Metastatic Castration-Resistant Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by ECOG-ACRIN Cancer Research Group. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by ECOG-ACRIN Cancer Research Group · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
9th of 59
432 · median 80
Started
2027
the only one that year
Phase 2/3
2 of 59
2 open now
Primary completion
2029-03
later than 31 of 39 live
Registered
59th of 59
by date
Lead sponsor
2 of 59
ECOG-ACRIN Cancer Research Group

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 9th largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 2/3, reaches primary completion later than 31 of the 39 other live ones, and was the 59th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant). Usual care treatment for patients with metastatic prostate cancer includes surgery or medical castration which involves drugs to suppress the function of the testes. After receiving this therapy, a period of disease stability occurs, followed typically by cancer regrowth and castration-resistant disease. Castration-resistant prostate cancer occurs because the tumor cells are eventually able to adapt to the very low levels of testosterone in the body. A new type of therapy called Bipolar Androgen Therapy (BAT) involves giving patients very high doses of testosterone every 28 days. This results in a cycle of higher than normal testosterone levels (i.e., "supraphysiologic") to near castrate levels over the 28 days. BAT may be able to stop prostate tumor cells from becoming castrate-resistant. In this trial, patients who receive BAT with high dose testosterone and experience disease progression then receive darolutamide. Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Adding BAT with high dose testosterone prior to darolutamide after disease progression may help shrink or stabilize metastatic castration-resistant prostate cancer better than usual treatments alone.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate if BAT followed by darolutamide (Arm B) is associated with improved second progression-free survival (PFS2) post second treatment compared to physician's choice standard of care (SOC)1 followed by SOC2 (Arm A) in men with mCRPC who have progressed on prior androgen receptor pathway inhibitor (ARPI). (Phase II) II. To evaluate if BAT followed by darolutamide (Arm B) is associated with improved overall survival (OS) compared to physician's choice SOC1 followed by SOC2 (Arm A) in men with mCRPC who have progressed on prior ARPI. (Phase III) III. To compare overall quality of life, measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score, between Arms A and B. (Quality of Life [QOL] objective)

SECONDARY OBJECTIVES:

I. To evaluate the radiographic progression-free survival (PFS) following initial randomization (Arm A SOC1 versus [vs] Arm B BAT) and following second treatment (Arm A SOC 2 vs Arm B darolutamide) as determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (for soft tissue metastases) and Prostate Cancer Working Group 3/PCWG3 criteria (for bone metastases).

II. To evaluate the PSA50 response (PSA decline ≥ 50% from baseline) rate following initial randomization (Arm A SOC1 vs Arm B BAT) and following second treatment (Arm A SOC2 vs Arm B darolutamide).

III. To evaluate the radiographic response rate following initial randomization (Arm A SOC1 vs Arm B BAT) and following second treatment (Arm A SOC2 vs Arm B darolutamide) per RECIST 1.1 criteria.

IV. To evaluate the incidence and severity of adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).

V. To compare overall quality of life, measured by FACT-P total score, at 12 weeks between Arms A and B. (QOL objective) VI. To compare the change in overall QOL, measured by FACT-P total score, from baseline to 12 weeks between Arms A and B. (QOL objective) VII. To compare patient-reported fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue] scores) at 12 weeks between Arms A and B. (QOL objective) VIII. To compare patient-reported overall QOL (FACT-P scores), and fatigue (FACIT-Fatigue scores) between Arms A and B at the time of first and second disease progression. (QOL objective) IX. To characterize longitudinal change in overall QOL (FACT-P) and fatigue (FACIT-Fatigue between baseline and second disease progression in Arms A and B. (QOL objective)

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive an SOC1 treatment regimen per discretion of the patient and the treating provider: 1) Docetaxel intravenously (IV) every 21 days with or without prednisone; OR 2) Abiraterone acetate orally (PO) once daily (QD) with prednisone or methylprednisolone or dexamethasone; OR 3) Enzalutamide PO QD. SOC1 treatment continues in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression then receive an SOC2 treatment regimen per discretion of the patient and the treating provider: 1) Docetaxel IV every 21 days with or without prednisone; OR 2) cabazitaxel IV every 21 days; OR 3) lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) IV every 6 weeks for 6 doses; OR 4) Abiraterone acetate PO QD with prednisone or methylprednisolone or dexamethasone; OR 5) Enzalutamide PO QD. SOC2 treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI), bone imaging, and biospecimen collection throughout the study.

ARM B: Patients receive testosterone cypionate intramuscularly (IM) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression then receive darolutamide PO twice daily (BID) in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, bone imaging, and biospecimen collection throughout the study.

After completion of study treatment, patients are followed every 3 months for 24 months from randomization and then every 6 months for 60 months from randomization.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient must be ≥ 18 years of age
  • Patient must have an (ECOG) Performance Status of 0-2
  • Patient must have documented confirmed adenocarcinoma of the prostate
  • Patient must have evidence of castration resistant prostate cancer (mCRPC) defined by Prostate Cancer Working Group 3 criteria as follows:

    • Prostate-specific antigen (PSA) progression defined as PSA ≥ 2 ng/mL and rising on two successive measurements at least 14 days apart (most recent PSA value must be within 28 days prior to randomization) AND
    • Castrate serum testosterone level ≤ 50 ng/dL
  • Patient must not be on systemic medication, including (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g., "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
  • Patients must have progressed on prior androgen receptor pathway inhibitors (ARPI) including, but not limited to, abiraterone, enzalutamide, apalutamide, or darolutamide. There must be at least a 2-week after stopping ARPI prior to randomization

    • NOTE: Prior bicalutamide is allowed and does not count as an ARPI
  • Patient must not have prior chemotherapy for the treatment of mCRPC. Patient may have received docetaxel for the treatment of hormone-sensitive prostate cancer

    • NOTE: This includes high dose testosterone therapy for prostate cancer
  • Patient must have at least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT, MRI and/or bone scan and is suitable for repeated assessment. Baseline imaging must be obtained within 28 days prior to randomization
  • Patient must not have current cancer-related pain requiring the use of opiates at the time of randomization
  • Patient must not have received any systemic therapy or radiotherapy within 14 days prior to randomization

    • NOTE: Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist treatment is allowed
  • Patient must not have evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy (i.e., femoral metastases with concern over fracture risk, spinal or epidural metastases with concern over spinal cord compression)
  • Patient must not have tumor causing urinary outlet obstruction that requires self-catheterization for voiding. Patients with indwelling catheter (e.g., foley or suprapubic catheter) for urinary obstruction are eligible. Patients that require catheterization to void secondary to benign strictures or other non-cancer causes are eligible
  • Patient must not have prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to randomization unless they are receiving therapeutic anticoagulation
  • Patient must not expect to father children by using accepted and effective method(s) of or by abstaining from heterosexual intercourse for the duration of their participation in this study treatment and for four months after the last dose of Arm A protocol treatment and for 3 months after the last dose of Arm B protocol treatment
  • Patient must have the ability to understand and the willingness to sign a written document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
  • (Hgb) > 7 g/dL and \< 17 g/dL (obtained ≤ 14 days prior to protocol randomization)
  • Leukocytes ≥ 3,000/mm\^3 (obtained ≤ 14 days prior to protocol randomization)
  • (ANC) ≥ 1,500/mm\^3 (obtained ≤ 14 days prior to protocol randomization)
  • ≥ 100,000/mm\^3 (obtained ≤ 14 days prior to protocol randomization)
  • Total ≤ 1.5 x institutional (ULN) (obtained ≤ 14 days prior to protocol randomization)
  • (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) ≤ 3.0 × institutional ULN (obtained ≤ 14 days prior to protocol randomization)
  • Estimated (eGFR) ≥ 30 mL/min/1.73 m\^2 (obtained ≤ 14 days prior to protocol randomization)
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Patients with new or progressive brain metastases (active brain metastases) or are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2 or better
  • Patient must be English or Spanish speaking to be eligible for the QOL component of the study

    • NOTE: Sites cannot translate the associated QOL forms
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
432 participants (estimated)

Study arms

  • Active comparator
    Arm A (SOC1, SOC2)

    Patients receive an SOC1 treatment regimen per discretion of the patient and the treating provider: 1) Docetaxel IV every 21 days with or without prednisone; OR 2) Abiraterone acetate PO QD with prednisone or methylprednisolone or dexamethasone; OR 3) Enzalutamide PO QD. SOC1 treatment continues in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression then receive an SOC2 treatment regimen per discretion of the patient and the treating provider: 1) Docetaxel IV every 21 days with or without prednisone; OR 2) cabazitaxel IV every 21 days; OR 3) 177Lu-PSMA-617 IV every 6 weeks for 6 doses; OR 4) Abiraterone acetate PO QD with prednisone or methylprednisolone or dexamethasone; OR 5) Enzalutamide PO QD. SOC2 treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, bone imaging, and biospecimen collection throughout the study.

    Drug: Abiraterone Acetate · Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabazitaxel · Procedure: Computed Tomography · Drug: Dexamethasone · Drug: Docetaxel · Drug: Enzalutamide · Drug: Lutetium Lu 177 Vipivotide Tetraxetan · Procedure: Magnetic Resonance Imaging · Drug: Methylprednisolone · Drug: Prednisone · Other: Questionnaire Administration

  • Experimental
    Arm B (testosterone cypionate, darolutamide)

    Patients receive testosterone cypionate IM on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression then receive darolutamide PO BID in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, bone imaging, and biospecimen collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Drug: Darolutamide · Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration · Drug: Testosterone Cypionate

Interventions

  • Given PO

    Also known as: BR9004, BR9004-1, CB 7630, CB-7630, CB7630, JNJ-212082, Yonsa, Zytiga

  • ProcedureBiospecimen Collection

    Undergo biospecimen collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Scan

    Undergo bone imaging

    Also known as: Bone Scintigraphy

  • Given IV

    Also known as: Jevtana, RPR 116258A, RPR-116258A, RPR116258A, Taxoid XRP6258, TXD 258, TXD-258, TXD258, XRP 6258, XRP-6258, XRP6258

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given PO

    Also known as: Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201

  • Given dexamethasone

    Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex

  • Given IV

    Also known as: Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate

  • Given PO

    Also known as: ASP9785, MDV 3100, MDV-3100, MDV3100, Xtandi

  • DrugLutetium (¹⁷⁷Lu) vipivotide tetraxetanStudies of Lutetium (¹⁷⁷Lu) vipivotide tetraxetanLutetium (¹⁷⁷Lu) vipivotide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 177Lu-labeled PSMA-617, 177Lu-PSMA-617, AAA 617, AAA-617, AAA617, Lu177-PSMA-617, Lutetium Lu 177-PSMA-617, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Lutetium-177-PSMA-617, Pluvicto

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given methylprednisolone

    Also known as: Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort

  • Given prednisone

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugTestosterone 17 beta-cypionateStudies of Testosterone 17 beta-cypionateTestosterone 17 beta-cypionate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IM

    Also known as: depAndro, Depo-Testosterone, Depotest, Depovirin, Pertestis, Virilon

06

What researchers measure

Primary outcomes

  1. Second progression-free survival (PFS2) (Phase II)

    Definition of progression includes radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Prostate Cancer Working Group 3 (PCWG3) for bone lesions, and clinical progression determined by treating physician. The phase II part will be conducted first and only if the treatment of Bipolar Androgen Therapy (BAT) followed by darolutamide significantly improves PFS2 compared to the SOC (SOC1 followed by SOC2) arm, then the study will continue to the phase III part. The primary comparisons will be an intention-to-treat analysis including all randomized patients. The phase II part of the study will have 89.5% power to detect the above difference in PFS2 using a one-sided 0.15 level stratified log-rank test.

    Time frame: From randomization to disease progression or death, whichever occurs first after initiation of second treatment (standard of care [SOC]2 or darolutamide), assessed up to 60 months

  2. Overall survival (OS) (Phase III)

    The phase II part will be conducted first and only if the treatment of BAT followed by darolutamide significantly improves PFS2 compared to the SOC (SOC1 followed by SOC2) arm, then the study will continue to the phase III part. The primary comparisons will be an intention-to-treat analysis including all randomized patients.

    Time frame: From randomization until death from any cause or date last known alive, assessed up to 60 months

  3. Overall quality of life (QOL)

    Will compare overall QOL, measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score, between the two arms. Mixed-effects models will be constructed, utilizing all available data, with fixed effects for treatment arm, assessment time, and the treatment-by-time interactions. A random intercept per patient will be included to account for within-subject correlations. Patients will rate physical, social/family, emotional, and functional well-being along with additional concerns on a scale from "not at all" to "very much". Interpretation of higher vs. lower scores being better is dependent on which subsection is being scored (i.e."I am able to work" rated as very much is not comparable to "I feel sad" rated as very much).

    Time frame: At randomization,12, 24 and 48 weeks after randomization

Secondary outcomes

  1. Progression-free survival (PFS)

    Will be determined using RECIST 1.1 criteria (for soft tissue metastases) and PCWG3 criteria (for bone metastases). Will be evaluated for each of the two treatments in a given arm.

    Time frame: From randomization to disease progression or death, whichever occurs first prior to initiation of the second treatment of the study, assessed up to 60 months

  2. PFS

    Will be determined using RECIST 1.1 criteria (for soft tissue metastases) and PCWG3 criteria (for bone metastases). Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initiation of second treatment to disease progression, clinical progression, or death, whichever occurs first, assessed up to 60 months

  3. Radiographic response rate

    Will be determined using RECIST 1.1 criteria. Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initial randomization up to 60 months

  4. Radiographic response rate

    Will be determined using RECIST 1.1 criteria. Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initiation of second treatment up to 60 months

  5. Prostate-specific antigen (PSA) decline ≥ 50% from baseline (PSA50) response

    Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initial randomization up to 60 months

  6. PSA50 response

    Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initiation of second treatment up to 60 months

  7. PSA PFS

    Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initial randomization to PSA progression or date of last disease assessment prior to initiation of second treatment, assessed up to 60 months

  8. PSA PFS

    Will be evaluated for each of the two treatments in a given arm.

    Time frame: From initiation of second treatment to PSA progression or date of last disease assessment, assessed up to 60 months

  9. Overall QOL

    Will compare overall QOL, measured by FACT-P total score, between the two arms at 12 weeks after randomization. Patients will rate physical, social/family, emotional, and functional well-being along with additional concerns on a scale from "not at all" to "very much". Interpretation of higher vs. lower scores being better is dependent on which subsection is being scored (i.e."I am able to work" rated as very much is not comparable to "I feel sad" rated as very much).

    Time frame: At 12 weeks after randomization

  10. Overall QOL

    A two-sample t test will be performed to compare the changes in FACT-P scores between the two arms. Patients will rate physical, social/family, emotional, and functional well-being along with additional concerns on a scale from "not at all" to "very much". Interpretation of higher vs. lower scores being better is dependent on which subsection is being scored (i.e."I am able to work" rated as very much is not comparable to "I feel sad" rated as very much).

    Time frame: From baseline to 12 weeks after randomization

  11. Overall QOL

    The FACT-P total scores at the time of first progression will be compared between the two arms. Patients will rate physical, social/family, emotional, and functional well-being along with additional concerns on a scale from "not at all" to "very much". Interpretation of higher vs. lower scores being better is dependent on which subsection is being scored (i.e."I am able to work" rated as very much is not comparable to "I feel sad" rated as very much).

    Time frame: At the time of first progression

  12. Overall QOL

    The FACT-P total scores at the time of second progression will be compared between the two arms. Patients will rate physical, social/family, emotional, and functional well-being along with additional concerns on a scale from "not at all" to "very much". Interpretation of higher vs. lower scores being better is dependent on which subsection is being scored (i.e."I am able to work" rated as very much is not comparable to "I feel sad" rated as very much).

    Time frame: From date of randomization until the date of second documented progression or date of death from any cause, whichever came first, assessed up to 60 months.

  13. Patient-reported fatigue

    Will be evaluated by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and compared between the two arms using a two-sample t test. Mixed effect models will be constructed to estimate the time profile of FACIT-Fatigue assessments in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in FACIT-Fatigue assessments over time or a set of dummy variables if non-linear trend exists.

    Time frame: 12 weeks after randomization date

  14. Patient-reported fatigue

    A two-sample t test will be performed to compare the changes in FACIT-Fatigue scores between the two arms. Mixed effect models will be constructed to estimate the time profile of FACIT-Fatigue assessments in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in FACIT-Fatigue assessments over time or a set of dummy variables if non-linear trend exists.

    Time frame: From baseline to 12 weeks after randomization

  15. Patient-reported fatigue

    Will be compared between the two arms. Mixed effect models will be constructed to estimate the time profile of FACIT-Fatigue assessments in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in FACIT-Fatigue assessments over time or a set of dummy variables if non-linear trend exists.

    Time frame: At the time of first progression

  16. Patient-reported fatigue

    Will be compared between the two arms. Mixed effect models will be constructed to estimate the time profile of FACIT-Fatigue assessments in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in FACIT-Fatigue assessments over time or a set of dummy variables if non-linear trend exists.

    Time frame: From date of randomization until the date of second documented progression or date of death from any cause, whichever came first, assessed up to 60 months.

Other outcomes

  1. Estimates of the primary outcome treatment effect by sex

    Will estimate the primary outcome treatment effect and the corresponding 95% confidence intervals (CIs) by sex.

    Time frame: From randomization until death from any cause or date last known alive, assessed up to 60 months

  2. Estimates of the primary outcome treatment effect by race

    Will estimate the primary outcome treatment effect and the corresponding 95% CIs by race.

    Time frame: Up to 60 months

  3. Estimates of the primary outcome treatment effect by ethnicity

    Will estimate the primary outcome treatment effect and the corresponding 95% CIs by ethnicity.

    Time frame: Up to 60 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2029, 26 months later.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Oct 1, 2026
StartEst.
Jan 6, 2027
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07852195
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Jan 6, 2027 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Michael Schweizer
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion